Kornimate/medical-research-clean huggingface dataset:
photodynamic treatment as part of oral healthcare on persons with sjögren's syndrome

Conditions: Sjogren Syndrome; Xerostomia

Summary: this thesis study will investigate whether the regular use of antibacterial photodynamic therapy can alleviate dry mouth symptoms in patients with sjogren's syndrome and thus be a potential addition to regular oral self-care habits that promote and maintain oral health.

sjogren's syndrome is a chronic autoimmune disease that has a holistic impact on a patient's health. the most significant consequence in terms of oral health is the destruction of the salivary glands by the autoimmune reaction, leading to salivary gland failure and consequently dry mouth with reduced saliva secretion. decreased saliva secretion predisposes to a number of oral health problems, and patients with sjogren's syndrome are therefore at risk for conditions such as caries and periodontitis, an inflammatory periodontal disease. regular visits to an oral health professional and good oral hygiene and eating habits and habits promote and maintain oral health. treatments for dry mouth symptoms associated with sjogren's syndrome aim to relieve oral symptoms by preserving, replacing and stimulating salivary gland secretion in ways that relieve local inflammation. regular home-use of specially designed antibacterial photodynamic therapy device in addition to standard oral self-care has been shown to destroy oral disease-causing bacteria in a way that bacteria cannot develop resistance to. in addition, the treatment method also stimulates saliva production through photobiomodulation. the aim of our study is therefore to investigate, by means of a clinical measurement, whether the regular use of the antibacterial photodynamic therapy device as part of oral self-care can have an effect on the amount of stimulated saliva secretion of a patient with sjogren's syndrome during the ten-week study period. the aim is also to describe, by means of a questionnaire measuring the subjective symptoms of dry mouth, whether the treatment has an effect on the frequency of the typical symptoms of xerostomia.

Eligibility criteria:
inclusion criteria: * adult (minimum 18 years of age) person with sjogren's syndrome, with dry mouth symptoms but some saliva secretion. * otherwise perceived health good, primary sjögren's syndrome patient. * no need for antibiotic prophylaxis at the time of a limited oral examination. * signed written informed consent. * subject's co-operation allows participation in the study. exclusion criteria: * pregnancy and/or breastfeeding. * fungal infection in the mouth * poor oral health, such as caries lesions or advanced periodontitis. * fixed dentures, or orthodontics. * no saliva secretion. * bisphosphonate drugs, multiple (more than two) medications in use. * participation in other oral health research at the same time.

Keywords: sjögren&amp;#39;s syndrome xerostomia apdt antibacterial photodynamic therapy photobiomodulation
influence of pramipexole on the qt interval of the ecg in healthy male and female volunteers

Conditions: Healthy

Summary: the objective of the study is to assess that pramipexole does not prolong the qt interval more than placebo


Eligibility criteria:
inclusion criteria: * all participants in the study need to be healthy males or females 21 to 50 years of age * body mass index (bmi) ranging from 18.5 to 29.9 kg/m2 * signed written informed consent prior to admission to the study in accordance with good clinical practice and the local legislation exclusion criteria: * any finding of the medical examination (including blood pressure, pulse rate and ecg) deviating from normal and of clinical relevance * gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders * history of orthostatic hypotension, fainting spells or blackouts * chronic or relevant acute infections * history of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator * intake of drugs with a long half-life (\> 24 hours) within at least one month or less than ten half-lives of the respective drug before enrolment in the study or during the study * use of any drugs which might influence the results of the trial up to 7 days prior to enrolment in the study or during the study * participation in another trial with an investigational drug (≤ 30 days prior to administration or during the trial) * heavy smoker (\> 10 cigarettes or \> 3 cigars of \> 3 pipes/day) * inability to refrain from smoking on trial days * alcohol abuse (\> 60 g/day) * drug abuse * blood donation (≥ 100 ml within four weeks prior to administration or during the trial) * any deviation of a laboratory value that is considered to be of clinical relevance * excessive physical activities within the last week before the trial or during the trial * hypersensitivity to pramipexole, moxifloxacin and/or related drugs of these classes * supine blood pressure at screening of systolic \< 100 mmhg and diastolic \< 60 mmhg * heart rate at screening of \> 80 beats per minute (bpm) or \< 40 bpm * any screening ecg value outside of the reference range of clinical relevance including, but not limited to pulse rate interval \> 220 ms, qrs interval \> 115 ms, qtcb or qtcf \> 450 ms, or qt (uncorrected) \> 470 ms * subjects involved in passenger transport or operation of dangerous machines for female subjects: * pregnancy * positive pregnancy test * no adequate contraception (adequate contraception: e.g. sterilization, intrauterine device, oral contraceptives) * inability to maintain this adequate contraception during the whole study period * lactation period
a trial of the combined impact of intermittent preventive treatment and insecticide treated bednets in reducing morbidity from malaria in african children

Conditions: Malaria

Summary: an investigation will be made of the combined impact of insecticide-treated nets and intermittent preventive treatment with amodiaquine + sulfadoxine-pyrimethamine on malaria morbidity in children in burkina faso and mali.three rounds of treatment will be given during the malaria season in one year and the follow-up will be extended into the second year by passive surveillance.

the trial will be conducted in 6000 children in burkina faso and mali in 2008 and 2009. each site will enroll 3,000 children. all children will be allocated a long lasting insecticide-treated net and randomized to receive to treatment (amodiaquine + sulfadoxine-pyrimethamine (aq+sp)) or placebo (aq-placebo + sp-placebo. treatment will be administered over 3 rounds during the high malaria transmission season, with one month interval between rounds. full course treatment of aq and sp will be administered on each occasion. treatment will not be given in the second year. passive surveillance of malaria will be implemented for the monitoring of malaria morbidity and to assess whether children who received intermittent preventive treatment (ipt) are at increased risk of malaria. adverse events will be monitored during each round of ipt administration. to assess the effect of iptc on the prevalence of malaria infection, a random sample of 150 children will be visited every week during the high malaria transmission period. this number will be increased to 300 during the low transmission season, but the survey will be reduced to monthly visits. baseline prevalence of genetic markers of resistance to sp and aq will be estimated. a second cross-sectional survey will be conducted at the end of the malaria transmission season to assess the effect of ipt on the prevalence of genetic markers of resistance to sp and aq, on the prevalence of anaemia and on nutritional indicators.

Eligibility criteria:
inclusion criteria: * permanent residence in the study area with no intention of leaving during the surveillance period. * obtention of informed consent. exclusion criteria: * temporary residence in the study area. * absence of informed consent. * presence of a severe, chronic illness such as severe malnutrition (kwashiorkor or marasmus) or aids, likely to interfere with evaluation of the trial results. * a history of a previous, significant adverse reaction to either of the study drugs.

Keywords: intermittent preventive treatment insecticide treated bednets malaria
evaluation of the effectiveness of genicular block in postoperative analgesia in patients undergoing knee arthroscopy

Conditions: Knee Pain Chronic

Summary: the effectiveness of genicular block in postoperative analgesia management in arthroscopy cases are intended to be evaluated.

relieving postoperative arthroscopy pain requires multimodal approaches of pain the most common treatment options are nonsteroidal anti-inflammatory drugs (nsaids), opioids and local infiltration of anesthetics is used. due to the side effects of nsaids and opioids application of regional analgesia techniques, while providing better analgesia quality. it can reduce complications . peripheral blocks such as genicular block, reduce side effects by reducing the use of other analgesics . pain, it is considered one of the most important factors affecting the quality of recovery.

Eligibility criteria:
inclusion criteria: our patients who will be included in the research are patients who underwent arthroscopy under elective conditions. it consists of volunteers over the age of 18, regardless of gender. - exclusion criteria: * infection in the block area * coagulation disorder, * known allergy to local anesthetics * pregnancy * patient with neuropathy * uncooperative patient * the patient who refused to participate in the study * patients under 18 years of age
evaluation of bilayered cellular matrix (orcel) for the treatment of venous ulcers

Conditions: Venous Leg Ulcer; Venous Stasis Ulcer

Summary: this study was designed to evaluate the clinical benefits and safety of orcel in the treatment of venous ulcers. orcel and standard care were compared to standard care alone. standard care consisted of currently accepted compression therapy. patients were treated for 12 weeks. patients with healed ulcers were followed for an additional 12 weeks to assess durability of the healed wound.


Eligibility criteria:
inclusion criteria: * any race, between 18 and 85 years of age * male or female * chronic venous insufficiency * ulcer size between 2 and 20 sq cm, inclusive * ulcer present for at least one month * abi \>0.7 exclusion criteria: * decrease in wound size \>35% during screening phase * infection at the ulcer site * uncontrolled diabetes mellitus * previous treatment with excluded medications

Keywords: venous leg ulcer orcel compression therapy
influences of cane use on voluntary forward stepping movement and associated attentional demands in hemiplegic patients

Conditions: Stroke

Summary: the purpose of this study was to examine the influence of cane use on the movement, kinetics, and associated attentional demands of performing a voluntary forward stepping movement in patients with stroke and age-matched healthy adults.


Eligibility criteria:
inclusion criteria: healthy subjects * age ang sex are correspond with the stroke subjects(between 30 and 75 years old) * being willing to sign an informed consent approved by the human subjects committee of the national taiwan university hospital stroke subjects * between 30 and 75 years old * stroke confirmed by icd-10-cm (including i60, i61, i62, i63, i67, and i63.9) * first stroke with single side hemiplegia and received acute treatment at ntuh * being willing to sign an informed consent approved by the human subjects committee of the national taiwan university hospital * able to stand independently for 10 minutes and to forward step without ankle-foot orthosis * mini-mental state examination (mmse) score at least 24 excursion criteria: healthy subjects * having other neurological diseases, or moderate to severe neuromuscular or musculoskeletal disorders, or disorders from systematic diseases those would influence the belance or motor ability stroke subjects * having unstable vital sign, unconsciousness, or obvious cognitive, perception, and language impairment, and couldn't communicate with the experimenters * having other neurological diseases, or moderate to severe neuromuscular or musculoskeletal or cardiovascular disorders, or disorders from systematic diseases those will influence standing ability other than stroke * having hemi-neglect or hemi-anopia

Keywords: hemiplegia regular cane volitional stepping dynamic equilibrium attention dual task
acute intestinal necrosis- the preoperative diagnostic approach

Conditions: Acute Mesenteric Ischemia

Summary: to investigate a number of blood based parameters in patients with intestinal ischaemia compared to patients with other acute abdominal diseases.

intestinal ischemia is a life-threatening condition defined by interrupted blood supply to the intestinal tissue. primary and secondary ischemia is obstruction of blood-supply due to vascular and extra-vascular pathology, respectively. early diagnosis and treatment are critical to save the ischemic bowel. clinical findings of secondary intestinal ischaemia are related to the underlying cause e.g. vomiting and palpable hernia. abdominal computed tomography (ct) can effectively visualize the causes. in contrast, the diagnosis of primary intestinal ischemia is often delayed due to the absence of specific clinical findings. primary intestinal ischemia is visualized with ct ateriography, revealing mesentery arterial obstruction. however, in the acute setting a non-arterial phase ct is often performed but the findings are unspecific in the early stages and the pattern of findings which could indicate primary ischemia are not well understood. in primary and secondary ischemia, standard blood-based parameters are inconsistently elevated and highly unspecific. newer blood-based parameters such as d-lactate has been proposed as ischaemic markers. d-lactate is produced by bacteria in the bowel lumen and translocation through a damaged bowel wall makes it a potential marker of intestinal ischemia. a case-control-study of all acute admitted patients with abdominal pain in aalborg, denmark in the mentioned time range. the sensitivity and specificity of potiential biomarkers in a blood sample at time of admission as a marker of intestinal ischaemia will be examined.

Eligibility criteria:
inclusion criteria: * referred to the department of gastrointestinal surgery, aalborg university hospital. exclusion criteria: * children
treatment of rheumatoid hand with magnetotherapy

Conditions: Rheumatoid Arthritis; Hand Rheumatism

Summary: brief summary: participants with rheumatoid arthritis with recommendation to physiotherapy. created 2 study groups: 1. kinesiotherapy with static magnetic field 2. kinesiotherapy with low-frequency pulsed magnetic field pulsed magnetic field give better effects then static magnetic field.

participants with rheumatoid arthritis with recommendation to physiotherapy. all participants have dysfunction and pain of hand. before entering the study, all patients were examined by a rheumatologist, who determined the degree of radiological and functional changes and measured blood pressure. patients with ii° and iii° of radiological and functional changes were qualified for the study. all the patients gave their informed consent to participate in the study. the examination included an overall assessment of functional status. patients were examined immediately before and after the intervention.

Eligibility criteria:
inclusion criteria: 1. informed voluntary consent to participate in the study 2. ii ° and iii ° of advancement of radiological changes 3. ii ° and iii ° of advancement of functional changes 4. remission, low or moderate ra activity: das28 5. medical referral for physiotherapy treatment exclusion criteria: 1. additional physiotherapy treatments for the hands 2. contraindications for magnetotherapy treatments 3. lack of informed, voluntary consent to participate in the study

Keywords: magnetotherapy rheumatoid arthritis hand function
intravenous continuous lmwh seems to be safe alternative to ufh in vv ecmo patients

Conditions: Refractory Respiratory Failure

Summary: unfractionated heparin (ufh) is worldwide anticoagulation used and recommended anticoagulation in patients with ecmo support. however, it is accompanied with incidence of bleeding or thrombotic compliaction at about 40-60% and high mortality. because ecmo produce primary haemosthasis pathology, there is a theory that prophylaxis of thrombosis with low molecular weight heparin (lmwh) e.g. enoxaparin might be sufficient to prevent ecmo throbosis and thrombosis development in patients. we decided to performed retrospective observation study and analysis of data, from may 2019 until august 2023, in all patients who were put on vv ecmo and to analysis incidence of bleeding, thrombotic and neurologic complications.

unfractionated heparin (ufh) is worldwide anticoagulation used and recommended anticoagulation in patients with ecmo support. however, it is accompanied with incidence of bleeding or thrombotic compliaction at about 40-60% and high mortality. because ecmo produce primary haemosthasis pathology, there is a theory that prophylaxis of thrombosis with low molecular weight heparin (lmwh) e.g. enoxaparin might be sufficient to prevent ecmo throbosis and thrombosis development in patients. this phenomenon of primary haemosthasis pathology may protect ecmo from thrombotic complication as primary haemosthasis plays major role in haemosthasis taking places in high shear stress condiditon such as ecmo. because lmwh is connected with lower incidence of bleeding complication and hit (heparin induced thrombocytopenia) in general, in case that patients on vv ecmo developed primary haemosthasis pathology detected by pfa 200, we started to use lmwh instead of ufh in vv ecmo patients. we decided to performed retrospective observation study and analysis of data, from may 2019 until august 2023, in all patients who were put on vv ecmo and to analysis incidence of bleeding, thrombotic and neurologic complications. we want to compare this incidence of compliactions with data known from patients with other studies using ufh.

Eligibility criteria:
inclusion criteria: * vv ecmo - use of 2 separate cannulas (jugular and femoral) * anticoagulation with only intravenous continuous lmwh (enoxaparin) * only a period of the first ecmo set running exclusion criteria: * pregnancy * avalon cannula (one double lumen cannula) * patients after thoraco-abdominal surgery * patients after lung transplantation in early postoperative period * patients after trauma without any type of heparin ,,heparin free" ecmo
maintaining and improving the intrinsic capacity involving primary care and caregivers

Conditions: Frailty; Frailty Syndrome; Frail Elderly Syndrome

Summary: the positive platform offers the possibility of unsupervised monitoring of pre-frailty and frailty status in a community setting, to detect the onset of frailty and to assess its evolution. the primary objective of the study is to evaluate whether the positive system improves frailty in at least 1 point in the fried's criteria and 5 points in the fts-5. this is a multi-centre, non-inferiority, randomized, simple blind and prospective pilot study with a 12-month follow up duration. the study will be carried out in spain, sweden and poland. 150 participants will be randomized into two groups. the control group will receive usual medical care. the intervention group will receive, in addition, the positive frailty home monitoring and intervention system.

the primary endpoints is to evaluate whether a multimodal intervention supported by the positive technological ecosystem improves frailty in at least 1 point in fried's criteria and 5 points in fts-5 during a 6-month follow-up period. this objective will be investigated through a multi-centre, non-inferiority, randomized, simple blind and prospective pilot study with an intervention lasting for 6 months. the study will be carried out in spain, sweden and poland. 150 participants (50 per site) will be randomized into two groups. the control group will receive usual medical care. the intervention group will receive, in addition, the positive frailty home monitoring and intervention system. both groups will be assessed with the same instruments. this assessment will be conducted at baseline (in the beginning of the trial period), at the middle (month 3) and at the end of the intervention (month 6). a stratified randomization technique will be applied in each of the study groups based on: age group (70-85,\> 85), history of cognitive impairment, history of stroke to guarantee the existence of comparable groups. these factors have been significantly associated with frailty and pre-frailty status (stroke or =3.11 (1.05-9.18), age, per 1-year or = 1.14 (1.08-1.21); cognitive impairment or = 8.37 (4.43-15.83)).

Eligibility criteria:
inclusion criteria: * age ≥ 70. * living at home. * having a caregiver/relative and/or supervision at home. * barthel ≥ 90. * meet at least 1 criterion from fried's criteria. exclusion criteria: * inadequate home infrastructure to host the required technology. * inability to understand on how to use the positive system by the participant. * diseases that may affect prescription therapy: * history of alcohol/drugs abuse. * living with another participant. * participating in other clinical studies. * three or more hospitalizations in the last year.

Keywords: frailty technology home monitoring older persons
dahuang gangtsao tang to improve the appetite loss condition of cancer patients

Conditions: Non-organic Loss of Appetite

Summary: appetite loss is a severe and common symptom among late-stage cancer patients, and it causes great the anxiety for the patient's family. in tcm theory, the investigators call these patients are in block and repulsion condition. the investigators try to set a study to use the herbal medicine solution taken in frequent small amounts by cancer patients in late-stage to improve the appetite loss condition. through this method, the investigators not only want to improve the quality of life of cancer patients in late-stage but also set a valuable treatment.

intervention group * 1. 2 grams of dahuang abstract powder and 0.5 grams gantsao abstract powder are mixed and separated into four packages; * 2. each package was given to each patient four times a day (three time after meal and one time before sleep); * 3. each patient received the usual medication of the hospice ward at the same time; * 4. record the patients' score of pre-test, mid-test and after-test of qipctp at the 1st day, the 3rd day and the 6th day; * 5. record the patients' score of eortc qlq-c30 v3.0 and ecog (eastern cooperative oncology group performance status) at the 1st day and the 6th day. control group * 1. each patient received the usual medication of the hospice ward during the trial interval; * 2. record the patients' score of receive pre-test, mid-test and after-test of qipctp at the 1st day, the 3rd day and the 6th day; * 3. record the patients' score of eortc qlq-c30 v3.0 and ecog (eastern cooperative oncology group performance status) at at the 1st day and the 6th day. medicine dahuang herbal abstract powder is produced by sun ten pharmaceutical co., ltd, and it's product serial number: 276001. gancao herbal abstract powder is also produced by sun ten pharmaceutical co., ltd, and it's product serial number: 185645. each herbal abstract powder is qualified with the data of hplc to confirm each content and stability. the pharmaceutical company is qualified by good manufacturing practice (gmp) certification in taiwan.

Eligibility criteria:
inclusion criteria: * terminal cancer patients in hospice ward * patients with appetite loss condition * ages between 20 to 80 years old * no history of diabetes exclusion criteria: * entered the stage of dying patients * receiving other traditional chinese medicine

Keywords: appetite loss